21:15 , Aug 7, 2019 |  BC Extra  |  Clinical News

Rhythm data sets up submissions for ultra-rare obesity disorders

Two new Phase III readouts pave the way for Rhythm Pharmaceuticals to make its first regulatory submissions for setmelanotide to treat rare genetic disorders that result in obesity. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Wednesday that...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:03 , Aug 22, 2018 |  BC Extra  |  Preclinical News

Inhibiting MMP2 reverses leptin resistance associated with obesity

University of California San Diego researchers and colleagues showed that inhibiting cleavage of leptin receptor (LEPR; CD295) by matrix metalloproteinase 2 (MMP2) could help prevent leptin resistance and treat obesity. Obesity is associated with high...
17:50 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Obesity Mouse studies suggest inhibiting IDO could help treat obesity. In a mouse model of high-fat diet-induced obesity, systemic IDO knockout decreased white adipose tissue (WAT), liver and body weights, lipid levels in the...
19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million on June 20 through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is...
14:14 , Jun 21, 2018 |  BC Extra  |  Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is an 8% discount...
19:22 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Other; gene therapy Caffeine-sensitive cell implants could be used to deliver gene therapies for diabetes and other diseases. The implants were generated by constructing a plasmid encoding a single-domain camelid antibody that homodimerizes in...
18:29 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

CHMP recommendations include Aimovig, orphan candidates

Among a host of positive recommendations announced on June 1, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin...
14:44 , Jun 1, 2018 |  BC Extra  |  Company News

CHMP's recommendations include Aimovig, Orphan candidates

Among a host of positive recommendations announced Friday, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin deficiency. The...